SMAD3 and renal fibrosis: Functional validation experiments demonstrated that silencing METTL3 using siRNA, genetic knockout, or treatment with the inhibitor STM2457 significantly reduced Smad3 expression, disrupted M2‐driven MMT, and alleviated renal fibrosis during CAR.